10.38
price up icon20.00%   1.73
after-market アフターアワーズ: 10.22 -0.16 -1.54%
loading
前日終値:
$8.65
開ける:
$9.75
24時間の取引高:
1.93M
Relative Volume:
2.13
時価総額:
$525.47M
収益:
$89.04M
当期純損益:
$-241.08M
株価収益率:
-1.9734
EPS:
-5.26
ネットキャッシュフロー:
$-194.72M
1週間 パフォーマンス:
+12.34%
1か月 パフォーマンス:
+0.68%
6か月 パフォーマンス:
+4.95%
1年 パフォーマンス:
+63.72%
1日の値動き範囲:
Value
$9.725
$10.76
1週間の範囲:
Value
$8.01
$10.76
52週間の値動き範囲:
Value
$5.035
$16.19

Regenxbio Inc Stock (RGNX) Company Profile

Name
名前
Regenxbio Inc
Name
セクター
Healthcare (1110)
Name
電話
240-552-8181
Name
住所
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Name
職員
353
Name
Twitter
@REGENXBIO
Name
次回の収益日
2025-08-01
Name
最新のSEC提出書
Name
RGNX's Discussions on Twitter

Compare RGNX vs VRTX, REGN, ARGX, ALNY, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
RGNX
Regenxbio Inc
10.38 437.89M 89.04M -241.08M -194.72M -5.26
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
460.87 116.01B 12.07B 3.95B 3.19B 15.33
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
781.60 80.33B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
740.40 44.42B 4.16B 1.29B 734.26M 19.59
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
323.59 42.53B 3.71B 313.75M 465.38M 2.2571
Biotechnology icon
ONC
Beone Medicines Ltd Adr
302.29 33.32B 5.36B 287.73M 924.18M 2.5229

Regenxbio Inc Stock (RGNX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-01-28 再開されました Barclays Overweight
2025-02-11 ダウングレード Goldman Buy → Neutral
2025-02-07 再開されました Raymond James Outperform
2024-11-15 再開されました Morgan Stanley Overweight
2024-10-10 再開されました Raymond James Outperform
2024-06-07 開始されました Goldman Buy
2024-03-11 開始されました H.C. Wainwright Buy
2024-03-08 アップグレード RBC Capital Mkts Sector Perform → Outperform
2024-03-06 アップグレード Leerink Partners Market Perform → Outperform
2024-02-21 再開されました Raymond James Outperform
2023-11-01 開始されました Stifel Buy
2023-06-02 開始されました Robert W. Baird Outperform
2022-06-23 開始されました Berenberg Buy
2021-12-15 開始されました Wedbush Neutral
2021-10-19 再開されました Morgan Stanley Overweight
2021-01-06 アップグレード Raymond James Outperform → Strong Buy
2020-12-16 開始されました UBS Buy
2020-06-25 再開されました BofA/Merrill Buy
2020-05-13 開始されました RBC Capital Mkts Sector Perform
2019-08-20 アップグレード SVB Leerink Underperform → Mkt Perform
2019-06-18 繰り返されました Chardan Capital Markets Buy
2019-06-14 再開されました Raymond James Outperform
2019-06-05 繰り返されました Chardan Capital Markets Buy
2019-02-25 アップグレード Evercore ISI In-line → Outperform
2019-02-05 アップグレード Raymond James Outperform → Strong Buy
2018-12-17 繰り返されました Chardan Capital Markets Buy
2018-11-08 繰り返されました BofA/Merrill Neutral
2018-08-08 繰り返されました Chardan Capital Markets Buy
2018-07-23 ダウングレード BofA/Merrill Buy → Neutral
2018-07-10 繰り返されました Chardan Capital Markets Buy
2018-05-09 繰り返されました Barclays Overweight
2018-04-09 繰り返されました Chardan Capital Markets Buy
2018-03-12 ダウングレード Evercore ISI Outperform → In-line
2018-02-13 開始されました Mizuho Neutral
2017-11-09 再開されました Morgan Stanley Overweight
すべてを表示

Regenxbio Inc (RGNX) 最新ニュース

pulisher
04:00 AM

RGNX'S "Transformational" Promise Became a $2.40 Loss for Investors: Levi & Korsinsky, LLP - GlobeNewswire

04:00 AM
pulisher
02:00 AM

Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.

02:00 AM
pulisher
01:31 AM

Portnoy Law Firm Announces Class Action on Behalf of REGENXBIO, Inc. Investors - GlobeNewswire

01:31 AM
pulisher
11:29 AM

Regenxbio at Leerink Global Healthcare Conference: Strategic Pipeline Advancements - Investing.com India

11:29 AM
pulisher
08:07 AM

H.C. Wainwright cuts Regenxbio stock price target to $30 - Investing.com

08:07 AM
pulisher
08:00 AM

Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire

08:00 AM
pulisher
07:21 AM

Regenxbio (RGNX): HC Wainwright Maintains Rating, Lowers Price T - GuruFocus

07:21 AM
pulisher
Mar 08, 2026

RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit - PR Newswire

Mar 08, 2026
pulisher
Mar 08, 2026

REGENXBIO commends women leadership driving mission on International Womens Day - Traders Union

Mar 08, 2026
pulisher
Mar 08, 2026

ROSEN, LEADING INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before ... - bdtonline.com

Mar 08, 2026
pulisher
Mar 08, 2026

ROSEN, LEADING INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.

Mar 08, 2026
pulisher
Mar 08, 2026

REGENXBIO Inc. (NASDAQ:RGNX) Q4 2025 Earnings Call Transcript - Insider Monkey

Mar 08, 2026
pulisher
Mar 07, 2026

Why REGENXBIO Inc. stock remains a top recommendation2026 Chart Watch & AI Based Trade Execution Alerts - Naître et grandir

Mar 07, 2026
pulisher
Mar 07, 2026

REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Mar 07, 2026
pulisher
Mar 07, 2026

RegenXbio Faces FDA Clinical Holds: Heightened Development Risk, Potential Delays, and Investor Uncertainty - TipRanks

Mar 07, 2026
pulisher
Mar 06, 2026

REGENXBIO Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm ... - bdtonline.com

Mar 06, 2026
pulisher
Mar 06, 2026

REGENXBIO Inc. Sued for Securities Law Violations – - GlobeNewswire

Mar 06, 2026
pulisher
Mar 06, 2026

Team powers gene therapy mission, REGENXBIO asserts - Traders Union

Mar 06, 2026
pulisher
Mar 06, 2026

The Analyst Verdict: Regenxbio In The Eyes Of 8 Experts - Benzinga

Mar 06, 2026
pulisher
Mar 06, 2026

Assessing Where Regenxbio Stands After FY25 Results (NASDAQ:RGNX) - Seeking Alpha

Mar 06, 2026
pulisher
Mar 06, 2026

RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire

Mar 06, 2026
pulisher
Mar 06, 2026

RGNX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO Investors of Securities Class Action Deadline on April 14, 2026 - PR Newswire

Mar 06, 2026
pulisher
Mar 06, 2026

Regenxbio: Q4 Earnings Snapshot - theheraldreview.com

Mar 06, 2026
pulisher
Mar 06, 2026

Morgan Stanley Lowers Price Target for RGNX but Maintains Overwe - GuruFocus

Mar 06, 2026
pulisher
Mar 06, 2026

REGENXBIO Q4 Earnings Call Highlights - MarketBeat

Mar 06, 2026
pulisher
Mar 05, 2026

REGENXBIO outlines 2026 Duchenne, wet AMD, and diabetic retinopathy milestones while targeting pivotal data releases - MSN

Mar 05, 2026
pulisher
Mar 05, 2026

RegenXBio Earnings Call Balances Gene Therapy Risks - TipRanks

Mar 05, 2026
pulisher
Mar 05, 2026

REGENXBIO (RGNX) Eyes Key Developments in 2026 Amid Robust Pipel - GuruFocus

Mar 05, 2026
pulisher
Mar 05, 2026

Regenxbio stock: Clear Street reiterates Buy on gene therapy data By Investing.com - Investing.com Canada

Mar 05, 2026
pulisher
Mar 05, 2026

Regenxbio stock: Clear Street reiterates Buy on gene therapy data - Investing.com

Mar 05, 2026
pulisher
Mar 05, 2026

REGENXBIO (NASDAQ:RGNX) Posts Earnings Results - MarketBeat

Mar 05, 2026
pulisher
Mar 05, 2026

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages REGENXBIO, Inc. Investors to Secure ... - Caledonian Record

Mar 05, 2026
pulisher
Mar 05, 2026

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages - GlobeNewswire

Mar 05, 2026
pulisher
Mar 05, 2026

Aug Catalysts: Is REGENXBIO Inc impacted by rising ratesQuarterly Profit Summary & Daily Technical Stock Forecast Reports - baoquankhu1.vn

Mar 05, 2026
pulisher
Mar 05, 2026

Morgan Stanley cuts Regenxbio stock price target on model updates - Investing.com Nigeria

Mar 05, 2026
pulisher
Mar 05, 2026

Morgan Stanley cuts Regenxbio stock price target on model updates By Investing.com - Investing.com Australia

Mar 05, 2026
pulisher
Mar 05, 2026

Regenxbio Inc (RGNX) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience By GuruFocus - Investing.com Canada

Mar 05, 2026
pulisher
Mar 05, 2026

Stifel cuts Regenxbio stock price target to $42 on gene therapy data - Investing.com UK

Mar 05, 2026
pulisher
Mar 05, 2026

RGNX'S "TRANSFORMATIONAL" PROMISE BECAME A $2.40 LOSS FOR INVESTORS: SUEWALLST - marketscreener.com

Mar 05, 2026
pulisher
Mar 05, 2026

Regenxbio Inc (RGNX) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience - GuruFocus

Mar 05, 2026
pulisher
Mar 05, 2026

Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire

Mar 05, 2026
pulisher
Mar 05, 2026

REGENXBIO (RGNX) Q4 2025 Earnings Call Transcript - The Globe and Mail

Mar 05, 2026
pulisher
Mar 05, 2026

Regenxbio Inc earnings missed by $0.58, revenue fell short of estimates - Investing.com UK

Mar 05, 2026
pulisher
Mar 05, 2026

Earnings call transcript: Regenxbio misses Q4 2025 expectations, stock dips - Investing.com

Mar 05, 2026
pulisher
Mar 05, 2026

REGENXBIO Inc. Q4 2025 Earnings Call Summary - Yahoo Finance

Mar 05, 2026
pulisher
Mar 05, 2026

Regenxbio: Fourth Quarter Financial Overview - Bitget

Mar 05, 2026
pulisher
Mar 05, 2026

Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance

Mar 05, 2026
pulisher
Mar 05, 2026

REGENXBIO ($RGNX) Releases Q4 2025 Earnings - Quiver Quantitative

Mar 05, 2026
pulisher
Mar 05, 2026

Regenxbio Q4 revenue rises but loss widens as costs increase - TradingView

Mar 05, 2026
pulisher
Mar 05, 2026

Regenxbio Earnings Report: Q4 Overview - Benzinga

Mar 05, 2026
pulisher
Mar 05, 2026

REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights - Yahoo Finance

Mar 05, 2026

Regenxbio Inc (RGNX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$99.79
price up icon 1.41%
$29.53
price up icon 2.61%
$55.74
price up icon 6.13%
$102.16
price up icon 0.65%
$143.13
price up icon 2.14%
biotechnology ONC
$302.29
price up icon 0.39%
大文字化:     |  ボリューム (24 時間):